Sigrid Therapeutics, a Stockholm, Sweden-based company which specializes in obesity and diabetes management disease, raised $4M in funding.
The backers were not disclosed.
The company intends to use the funds to accelerate the commercialisation of SiPore® across diverse markets, including medical devices, food supplements, veterinary, and oral health.
Led by CEO Sana Alajmovic, Sigrid Therapeutics is dedicated to working for obesity and diabetes management through its SiPore® technology. Its flagship product, SiPore21®, is currently in SHINE clinical trials, offering a natural, non-drug solution for prediabetes progression and weight control. Administered orally, SiPore21® utilises a mesoporous silica mineral to prevent digestive enzymes from breaking down carbohydrates and fats, offering a promising alternative to pharmaceutical methods.
FinSMEs
31/10/2023